omeprazole has been researched along with levofloxacin in 48 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.08) | 18.2507 |
| 2000's | 24 (50.00) | 29.6817 |
| 2010's | 21 (43.75) | 24.3611 |
| 2020's | 2 (4.17) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Arpin, C; Ba, BB; Caignard, DH; Forfar-Bares, I; Grellet, J; Guillon, J; Jarry, C; Moreau, S; Quentin, C; Vidaillac, C | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Hibi, T; Muraoka, H; Nishizawa, T; Suzuki, H | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Aeschlimann, JR; Kaatz, GW; Rybak, MJ | 1 |
| Arancio, F; Armuzzi, A; Cammarota, G; Cannizzaro, O; Cianci, R; Cuoco, L; Gasbarrini, A; Gasbarrini, G; Pirozzi, G; Santarelli, L; Zocco, MA | 1 |
| Chan, CK; Fung, FM; Gu, Q; Hu, WH; Lai, KC; Lam, SK; Wong, BC; Wong, WM; Xia, HH; Yee, YK; Yuen, MF | 1 |
| Angeletti, S; De Francesco, V; Hassan, C; Ierardi, E; Lorenzetti, R; Marignani, M; Morini, S; Zullo, A | 1 |
| Asaumi, N; Kiguchi, T; Masuda, K; Niiya, K; Niiya, M; Tanimoto, M; Yoshida, C | 1 |
| Andriulli, A; Barberani, F; Festa, V; Merla, A; Perri, F; Pilotto, A | 1 |
| Aoyama, N; Fukuda, M; Kachi, M; Kasuga, M; Kuroda, K; Maekawa, S; Miki, I; Shirasaka, D; Tamura, T; Wambura, C; Watanabe, Y | 1 |
| Branca, G; Cammarota, G; Cannizzaro, O; Cesaro, P; Cianci, R; di Caro, S; Fedeli, P; Gasbarrini, G; Lecca, PG; Martino, A | 1 |
| Accornero, L; Bilardi, C; Dulbecco, P; Iiritano, E; Mamone, M; Mansi, C; Parodi, A; Reglioni, S; Savarino, E; Savarino, V; Vigneri, S; Zentilin, P | 1 |
| Castro, LP; Cerqueira, MC; Cindr, JM; Coelho, LG; Gallo, MA; Mendonça, S; Moretzsohn, LD; Passos, MC; Pedrazzoli-Júnior, J; Ribeiro, ML; Vieira, WL; Vitiello, L | 1 |
| Bilardi, C; Dulbecco, P; Giannini, EG; Mamone, M; Mansi, C; Santi, ML; Savarino, V; Testa, R | 2 |
| Chan, AO; Chan, CK; Chu, KM; Fung, FM; Gu, Q; Lai, KC; Tong, TS; Wong, BC; Wong, WM; Yee, YK | 1 |
| Benito, LM; Bermejo, F; Bory, F; Castro-Fernández, M; Cosme, A; Ducons, J; Fernández-Bermejo, M; Gisbert, JP; Lamas, E; López-Rivas, L; Olivares, D; Pabón, M; Pérez-Aisa, A | 1 |
| Pistiolas, D; Robotis, J; Rokkas, T; Sechopoulos, P | 1 |
| Almela, P; Barrio, J; Benito, LM; Bermejo, F; Bory, F; Calvet, X; Carneros, JA; Castro-Fernández, M; Cosme, A; Fernández-Bermejo, M; Franco, A; García-Durán, F; Gisbert, JP; Khorrami, S; Lamas, E; Modolell, I; Niño, P; O'Callaghan, E; Ortiz, V; Ortuño, J; Pérez-Aisa, A; Ponce, J; Rodrigo, L; Sánchez-Pobre, P; Tomas, A; Valer, MP | 1 |
| Cantu, M; Ferguson, D; Page, RL | 1 |
| Andrés, PR; Bermejo, AB; Bermejo, MF; Gallardo, BP; García, GG; Gisbert, JP; Infante, JM; Rodríguez, JM | 1 |
| Barrio, J; Castro-Fernández, M; Cosme, A; Gisbert, JL; Gisbert, JP; Marcos, S; Moreno-Otero, R; Pérez-Aisa, A; Rodrigo, L | 1 |
| Abadia, EG; Dueñas, C; Fernandez-Bermejo, M; Gisbert, JP; Gonzalez-Garcia, G; Hernandez-Alonso, M; Mateos-Rodriguez, JM; Molina-Infante, J; Perez-Gallardo, B; Vinagre, G | 1 |
| Azad, MA; Faruquee, CF; Hasnat, A; Parveen, S; Rayhan, I; Ullah, A | 1 |
| Cristofari, F; De Francesco, V; Hassan, C; Manes, G; Scaccianoce, G; Zullo, A | 1 |
| Abdelfatah, M; Assem, M; El Azab, G; Rasheed, MA; Shastery, M | 1 |
| Choi, KH; Chung, WC; Jung, SH; Kang, BK; Kim, EJ; Lee, KM; Oak, JH; Paik, CN | 1 |
| Akyuz, F; Ermis, F; Kaymakoglu, S; Kurt, R; Mungan, Z; Nazik, H; Pinarbasi, B; Uyanikoglu, A | 1 |
| Basu, PP; Flynn, M; Krishnaswamy, N; Pacana, T; Rayapudi, K; Shah, NJ | 1 |
| Bagheri, H; Caillet, C; Chauvelot-Moachon, L; Montastruc, JL | 1 |
| Almela, P; Barrio, J; Bermejo, F; Bory, F; Calvet, X; Castro-Fernández, M; Cosme, A; Fernández-Bermejo, M; Franco, A; Gisbert, JP; Guerra, I; Khorrami, S; Lamas, E; Modolell, I; Ortuño, J; Pérez-Aisa, A; Ponce, J; Rodrigo, L; Sánchez-Pobre, P; Tomas, A | 1 |
| Bizzarri, B; de'Angelis, GL; Manfredi, M | 1 |
| Bonfrate, L; Castorani, L; D'Ambrosio, P; De Francesco, V; Hassan, C; Portincasa, P; Ruggiero, V; Scaccianoce, G; Vannella, L; Zullo, A | 1 |
| Fejza, H; Kraja, B; Manxhuka-Kerliu, S; Prifti, S; Qirjako, G; Telaku, S | 1 |
| Aisa, AP; Barrio, J; Castro-Fernández, M; Cosme, A; Fernández-Bermejo, M; Gisbert, JL; Gisbert, JP; Marcos, S; Marín, AC; McNicholl, AG; Modolell, I; Molina-Infante, J; Rodrigo, L | 1 |
| Al Kaabi, S; Babu, R; Chandra, P; Derbala, M; Doiphode, S; John, A; Sharma, M; Yacoub, R | 1 |
| Fukuda, H; Fukuda, S; Irie, M; Kunimoto, H; Morihara, D; Sakisaka, S; Shakado, S; Takata, K; Takeyama, Y; Tanaka, T; Umeda, K; Yamauchi, R; Yokoyama, K | 1 |
| Arj, A; Gilassi, H; Madani, M; Razavizadeh, M | 1 |
| Florholmen, JR; Goll, R; Halvorsen, FA; Johnsen, KM; Melby, KK; Moayeri, B; Nestegard, O; Paulssen, E; Sørbye, SW; Tønnesen, T | 1 |
2 review(s) available for omeprazole and levofloxacin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Fitz-Hugh-Curtis syndrome in a man positive for Chlamydia trachomatis.
Topics: Abdominal Pain; Anti-Bacterial Agents; Anti-Ulcer Agents; Chlamydia Infections; Chlamydia trachomatis; Drug Therapy, Combination; Duodenal Ulcer; Hepatitis; Humans; Levofloxacin; Male; Middle Aged; Omeprazole; Pelvic Inflammatory Disease; Peritonitis; Urine | 2018 |
19 trial(s) available for omeprazole and levofloxacin
| Article | Year |
|---|---|
Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Benzimidazoles; Female; Follow-Up Studies; Gastric Acid; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Omeprazole; Penicillins; Prospective Studies; Rabeprazole; Tinidazole | 2000 |
Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Benzimidazoles; Drug Resistance; Drug Therapy, Combination; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Omeprazole; Rabeprazole; Rifabutin; Treatment Outcome | 2003 |
Randomized study of different 'second-line' therapies for Helicobacter pylori infection after failure of the standard 'Maastricht triple therapy'.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Benzimidazoles; Bismuth; Breath Tests; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Metronidazole; Middle Aged; Ofloxacin; Omeprazole; Pantoprazole; Prospective Studies; Ranitidine; Sulfoxides; Tinidazole; Treatment Failure; Urea | 2003 |
High-dose versus low-dose clarithromycin in 1-week triple therapy, including rabeprazole and levofloxacin, for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Benzimidazoles; Breath Tests; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Ofloxacin; Omeprazole; Rabeprazole; Treatment Outcome | 2004 |
A 10-day levofloxacin-based therapy in patients with resistant Helicobacter pylori infection: a controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Humans; Levofloxacin; Male; Metronidazole; Middle Aged; Ofloxacin; Omeprazole; Organometallic Compounds; Pantoprazole; Prospective Studies; Sulfoxides; Treatment Outcome | 2004 |
A study of 4- and 7-day triple therapy with rabeprazole, high-dose levofloxacin and tinidazole rescue treatment for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Infective Agents; Antitrichomonal Agents; Benzimidazoles; Drug Administration Schedule; Drug Therapy, Combination; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Omeprazole; Pilot Projects; Rabeprazole; Time Factors; Tinidazole; Treatment Outcome | 2006 |
Lansoprazole, levofloxacin and amoxicillin triple therapy vs. quadruple therapy as second-line treatment of resistant Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Hong Kong; Humans; Lansoprazole; Levofloxacin; Male; Metronidazole; Middle Aged; Ofloxacin; Omeprazole; Organometallic Compounds; Tetracycline; Treatment Outcome | 2006 |
Third-line rescue therapy with levofloxacin after two H. pylori treatment failures.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Breath Tests; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibitors; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Metronidazole; Middle Aged; Ofloxacin; Omeprazole; Prospective Studies; Protein Synthesis Inhibitors; Tetracycline; Treatment Failure | 2006 |
Can Helicobacter pylori eradication regimens be shortened in clinical practice? An open-label, randomized, pilot study of 4 and 7-day triple therapy with rabeprazole, high-dose levofloxacin, and tinidazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Benzimidazoles; Breath Tests; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Ofloxacin; Omeprazole; Pilot Projects; Rabeprazole; Tinidazole; Treatment Outcome | 2006 |
Second-line rescue therapy with levofloxacin after H. pylori treatment failure: a Spanish multicenter study of 300 patients.
Topics: Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Therapy, Combination; Endoscopy, Gastrointestinal; Female; Follow-Up Studies; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Omeprazole; Prospective Studies; Proton Pump Inhibitors; Treatment Failure; Urea | 2008 |
Clinical trial: clarithromycin vs. levofloxacin in first-line triple and sequential regimens for Helicobacter pylori eradication.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Metronidazole; Middle Aged; Ofloxacin; Omeprazole; Treatment Outcome; Young Adult | 2010 |
Efficacy and safety of Levofloxacin, Clarithromycin and Esomeprazol as first line triple therapy for Helicobacter pylori eradication in Middle East. Prospective, randomized, blind, comparative, multicenter study.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Medication Adherence; Middle Aged; Ofloxacin; Omeprazole; Prospective Studies; Single-Blind Method; Young Adult | 2010 |
Efficacy of levofloxacin and rifaximin based quadruple therapy in Helicobacter pylori associated gastroduodenal disease: a double-blind, randomized controlled trial.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Diarrhea; Double-Blind Method; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Omeprazole; Peptic Ulcer; Prospective Studies; Rifamycins; Rifaximin | 2011 |
Second-line levofloxacin-based triple therapy's efficiency for Helicobacter pylori eradication in patients with peptic ulcer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Levofloxacin; Male; Middle Aged; Ofloxacin; Omeprazole; Peptic Ulcer; Treatment Outcome; Young Adult | 2011 |
A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Doxycycline; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Lansoprazole; Levofloxacin; Male; Middle Aged; Nitro Compounds; Ofloxacin; Omeprazole; Prospective Studies; Proton Pump Inhibitors; Recurrence; Thiazoles; Young Adult | 2011 |
Helicobacter pylori infection: sequential therapy followed by levofloxacin-containing triple therapy provides a good cumulative eradication rate.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Omeprazole; Treatment Outcome; Young Adult | 2012 |
Concomitant, sequential, and hybrid therapy for H. pylori eradication: a pilot study.
Topics: Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Omeprazole; Pilot Projects; Proton Pump Inhibitors; Tinidazole; Urea | 2013 |
The efficacy of levofloxacin-based triple therapy for first-line helicobacter pylori eradication.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Time Factors; Treatment Outcome; Young Adult | 2013 |
Comparing the Efficacy of Sequential and Standard Quadruple Therapy for Eradication of H. Pylori Infection.
Topics: Adult; Aged; Amoxicillin; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Omeprazole; Organometallic Compounds; Tinidazole | 2020 |
27 other study(ies) available for omeprazole and levofloxacin
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Synthesis of omeprazole analogues and evaluation of these as potential inhibitors of the multidrug efflux pump NorA of Staphylococcus aureus.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Culture Media; Drug Resistance, Multiple, Bacterial; Enzyme Inhibitors; Indicators and Reagents; Kinetics; Microbial Sensitivity Tests; Multidrug Resistance-Associated Proteins; Norfloxacin; Omeprazole; Staphylococcus aureus; Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Sitafloxacin and garenoxacin may overcome the antibiotic resistance of Helicobacter pylori with gyrA mutation.
Topics: Anti-Infective Agents; DNA Gyrase; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Helicobacter pylori; Mutation | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
The effects of NorA inhibition on the activities of levofloxacin, ciprofloxacin and norfloxacin against two genetically related strains of Staphylococcus aureus in an in-vitro infection model.
Topics: Anti-Infective Agents; Bacterial Proteins; Ciprofloxacin; Drug Interactions; Drug Resistance, Microbial; Enzyme Inhibitors; Humans; Levofloxacin; Microbial Sensitivity Tests; Models, Biological; Multidrug Resistance-Associated Proteins; Norfloxacin; Ofloxacin; Omeprazole; Species Specificity; Staphylococcal Infections; Staphylococcus aureus | 1999 |
A third-line levofloxacin-based rescue therapy for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Benzimidazoles; Breath Tests; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Endoscopy, Digestive System; Female; Glossitis; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Omeprazole; Penicillins; Prospective Studies; Rabeprazole; Treatment Outcome; Urea | 2003 |
[Helicobacter pylori eradication based upon a drug sensitivity test effectively increased platelet count in a patient with refractory idiopathic thrombocytopenic purpura].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Minocycline; Ofloxacin; Omeprazole; Platelet Count; Purpura, Thrombocytopenic, Idiopathic | 2003 |
Levofloxacin based triple therapy as a second-line treatment after failure of helicobacter pylori eradication with standard triple therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Ofloxacin; Omeprazole; Prospective Studies; Proton Pump Inhibitors; Treatment Failure | 2003 |
New once-daily, highly effective rescue triple therapy after multiple Helicobacter pylori treatment failures: a pilot study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Infective Agents, Local; Anti-Ulcer Agents; Benzimidazoles; Drug Combinations; Female; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Omeprazole; Pilot Projects; Rabeprazole; Treatment Outcome | 2005 |
Triple levofloxacin-based rescue therapy is an accepted empirical third-line treatment.
Topics: Amoxicillin; Ampicillin; Antacids; Anti-Bacterial Agents; Bismuth; Breath Tests; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Ofloxacin; Omeprazole; Protein Synthesis Inhibitors; Tetracycline; Treatment Failure | 2006 |
An alternative salvage regimen for Helicobacter pylori-resistant patients with heart failure.
Topics: Amoxicillin; Anti-Bacterial Agents; Comorbidity; Drug Therapy, Combination; Heart Failure; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Omeprazole; Proton Pump Inhibitors | 2008 |
Levofloxacin, Amoxicillin, and Omeprazole as first-line triple therapy for Helicobacter pylori eradication.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Female; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Omeprazole; Patient Compliance; Treatment Outcome | 2009 |
Helicobacter pylori first-line treatment and rescue option containing levofloxacin in patients allergic to penicillin.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug Administration Schedule; Drug Hypersensitivity; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Metronidazole; Middle Aged; Ofloxacin; Omeprazole; Penicillins; Prospective Studies; Treatment Outcome | 2010 |
Interaction study between levofloxacin and omeprazole using urinary pharmacokinetic data.
Topics: Adolescent; Adult; Drug Interactions; Female; Humans; Levofloxacin; Male; Ofloxacin; Omeprazole; Time Factors | 2010 |
Second-line and rescue therapies for Helicobacter pylori eradication in clinical practice.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Drug Administration Schedule; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Italy; Levofloxacin; Male; Medication Adherence; Middle Aged; Ofloxacin; Omeprazole; Practice Guidelines as Topic; Proton Pump Inhibitors; Rifabutin; Time Factors; Treatment Failure | 2010 |
Safety profile of enantiomers vs. racemic mixtures: it's the same?
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Cetirizine; Citalopram; Databases, Factual; Female; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Omeprazole; Stereoisomerism; Young Adult | 2012 |
Second-line therapy with levofloxacin after failure of treatment to eradicate helicobacter pylori infection: time trends in a Spanish Multicenter Study of 1000 patients.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Logistic Models; Male; Medication Adherence; Middle Aged; Multivariate Analysis; Ofloxacin; Omeprazole; Prospective Studies; Proton Pump Inhibitors; Remission Induction; Spain; Surveys and Questionnaires; Time Factors; Treatment Failure | 2013 |
Helicobacter pylori first-line and rescue treatments in the presence of penicillin allergy.
Topics: Antacids; Anti-Bacterial Agents; Bismuth; Breath Tests; Clarithromycin; Drug Administration Schedule; Drug Hypersensitivity; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Medication Adherence; Metronidazole; Middle Aged; Omeprazole; Penicillins; Predictive Value of Tests; Prospective Studies; Proton Pump Inhibitors; Rifabutin; Salvage Therapy; Spain; Tetracycline; Time Factors; Treatment Outcome | 2015 |
Does emerging Clarithromycin resistance signal an obituary to empirical standard triple therapy for Helicobacter pylori infection?
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Longitudinal Studies; Metronidazole; Omeprazole; Prospective Studies; Rifabutin; Tetracycline; Treatment Failure | 2015 |
Helicobacter pylori resistance to antibiotics before and after treatment: Incidence of eradication failure.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Helicobacter Infections; Helicobacter pylori; Humans; Incidence; Levofloxacin; Metronidazole; Microbial Sensitivity Tests; Omeprazole; Protein Synthesis Inhibitors; Tetracycline | 2022 |